A federal review board voted Thursday to loosen rules on seven peptides, including BPC-157 and TB-500. The vote was narrow. It is not final. The FDA has given no signal on whether it will take up the recommendation. The move came after weeks of community hearings. Wellness backers pressed firmly for wider access. RFK Jr. was among them. Critics say these compounds have insufficient safety data or help for most uses. The call could change how the agency handles a part of the wellness market that is moving at speed. Regulators are watching to see if the FDA picks up the plan. A spokesperson for the agency offered no firm timeline for a follow-up. Industry voices argue the change would open up access to products that users favor. Health groups warn that looser rules could leave gaps in oversight across a quickly growing market. The Thursday vote only opens the door to a change, and the final decision rests with the federal agency.